KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$0.04.

  • Arbutus Biopharma's EPS (Basic) rose 6000.0% to -$0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.23, marking a year-over-year increase of 4651.16%. This contributed to the annual value of -$0.38 for FY2024, which is 1438.5% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's EPS (Basic) is -$0.04, which was up 6000.0% from $0.01 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's EPS (Basic) ranged from a high of $0.01 in Q2 2025 and a low of -$0.24 during Q3 2021
  • Moreover, its 5-year median value for EPS (Basic) was -$0.11 (2022), whereas its average is -$0.12.
  • Within the past 5 years, the most significant YoY rise in Arbutus Biopharma's EPS (Basic) was 10909.09% (2025), while the steepest drop was 3000.0% (2025).
  • Quarter analysis of 5 years shows Arbutus Biopharma's EPS (Basic) stood at -$0.15 in 2021, then grew by 6.67% to -$0.14 in 2022, then rose by 14.29% to -$0.12 in 2023, then soared by 43.88% to -$0.07 in 2024, then skyrocketed by 40.6% to -$0.04 in 2025.
  • Its EPS (Basic) stands at -$0.04 for Q3 2025, versus $0.01 for Q2 2025 and -$0.13 for Q1 2025.